spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Daiichi-Sankyo 

 HSMN NewsFeed - 28 Oct 2021
Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2019
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 May 2019
Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Dec 2018
CStone Pharmaceuticals Appoints Former MSD Global Oncology Early Development Executive Director Archie Tse, M.D., Ph.D., as the newly established SVP, Chief Translation Medicine Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Nov 2018
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2018
Sosei Announces Appointment of Chris Cargill as Interim CFO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2017
CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA(R) (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 3 Apr 2017
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2011
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Biopharmaceuticals
 HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Oct 2010
Exelixis Licenses Programs to Bristol-Myers Squibb Company
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Jun 2010
New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)'s Effect on Bone Quality in Osteoporotic Patients
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2010
Exelixis Regains Full Rights to Develop and Commercialize XL184
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Jan 2010
Pieris Appoints a New CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2008
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2008
Fresenius Medical Care Announces Closing of the U.S. License Agreement for Intravenous Iron Products
Biopharmaceuticals Licensing
 HSMN NewsFeed - 22 Jan 2008
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jan 2008
GSK Does Not Option XL784 for Further Development
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Jan 2008
Exelixis Announces Senior Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2007
GlaxoSmithKline Accelerates Review of Exelixis' XL880
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2007
Abbott and Caprion Extend Partnership to Discover Antibody Targets for Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2006
BioMimetic Therapeutics Receives FDA Approval that Expands Manufacturing Capacity for GEM 21S(R)
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
Daiichi-Sankyo
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.